Jacqualyn Fouse compensation by year
AGIOS PHARMACEUTICALS Summary Compensation Table · all 4 fiscal years held| Component | FY2019 | FY2020 | FY2021 | FY2022 |
|---|---|---|---|---|
| Salary | $664,583 | $746,750 | $760,000 | $466,761 |
| Bonus | $0 | $0 | $0 | $0 |
| Stock awards | $2,538,474 | $1,751,340 | $0 | $1,408,188 |
| Option awards | $12,875,608 | $4,593,651 | $5,202,524 | $2,732,839 |
| Non-equity incentive | $424,125 | $509,657 | $543,400 | $292,950 |
| Pension and deferred compensation | $0 | $0 | $0 | $0 |
| All other | $105,204 | $10,577 | $13,503 | $10,311 |
| Total | $16,607,994 | $7,611,975 | $6,519,427 | $4,911,049 |
Each year as stated in that year's proxy. A dash means the company reported no figure in that column. Source: AGIOS PHARMACEUTICALS, INC. DEF 14A filed April 26, 2023, accession 0001193125-23-118490, and prior-year filings. Open the filing on EDGAR.
How this page was built: the AGIOS PHARMACEUTICALS, INC. filed document, accession 0001193125-23-118490. Every figure is read from that document and cited to the page and table it appears in. Filed April 26, 2023.
Equity holdings
unvested awards at FY2022 year-end| Type | Unvested units | Value at year-end | Exercise price |
|---|---|---|---|
| RSU | 47,800 | $1,342,224 | — |
| RSU | 11,333 | $318,231 | — |
| Option | 14,598 | — | $53.87 |
| Option | 170,000 | — | $29.46 |
| Option | 88,296 | — | $56.68 |
| Option | 39,962 | — | $51.51 |
Per the Outstanding Equity Awards at Fiscal Year-End table in AGIOS PHARMACEUTICALS, INC.'s FY2022 proxy; value at the fiscal year-end close, as the company printed it.
Insider transactions since the last proxy
29 Form 4 lines since the FY2022 proxy (filed April 26, 2023)current to 2026-11-21 · updated nightly
| Date | Transaction | Plan | Shares | Price | Held after |
|---|---|---|---|---|---|
| 2026-06-18 | Grant or award derivative | — | 14,950 | $0.00 | 14,950 |
| 2026-06-18 | Exercise or conversion derivative | — | 2,816 | $0.00 | 0 |
| 2026-06-18 | Grant or award derivative | — | 2,927 | $0.00 | 2,927 |
| 2026-06-18 | Exercise or conversion | — | 2,816 | $0.00 | 154,156 |
| 2025-06-20 | Exercise or conversion | — | 2,120 | $0.00 | 151,340 |
| 2025-06-20 | Exercise or conversion derivative | — | 2,120 | $0.00 | 0 |
| 2025-06-18 | Grant or award derivative | — | 15,768 | $0.00 | 15,768 |
| 2025-06-18 | Grant or award derivative | — | 2,816 | $0.00 | 2,816 |
The 8 most recent of 29 lines, each as reported on the Form 4. "10b5-1" marks a trade the filing reports under a pre-arranged trading plan. View every Form 4 filing on EDGAR →
AGIOS PHARMACEUTICALS’s named executive officers, FY2022
as the company reported each| Named executive officer | Role | FY2022 total |
|---|---|---|
| Brian Goff | Chief Executive Officer | $11,744,447 |
| Jacqualyn Fouse · this page | Former Chief Executive Officer | $4,911,049 |
| Cecilia Jones | Chief Financial Officer | $2,910,926 |
| Richa Poddar | Former Chief Commercial Officer | $1,926,456 |
| Bruce Car | Former Chief Scientific Officer | $1,852,384 |
| Sarah Gheuens | Chief Medical Officer, Head of Research & Development | $1,846,903 |
| James Burns | Chief Legal Officer | $1,738,025 |
| Jonathan Biller | Former Chief Financial Officer, Head of Corporate Affairs | $1,478,067 |
Board service
AGIOS PHARMACEUTICALS board · FY2021–FY2025| Fiscal year | Cash fees | Stock awards | Option awards | Other | Total |
|---|---|---|---|---|---|
| FY2025 | $92,500 | $99,968 | $299,689 | $0 | $492,157 |
| FY2024 | $87,500 | $89,994 | $266,287 | $0 | $443,781 |
| FY2023 | $87,500 | $89,985 | $269,767 | $0 | $447,252 |
| FY2022 | — | $47,800 | $170,000 | $0 | — |
| FY2021 | — | — | — | — | — |
Each year as the company reported it in AGIOS PHARMACEUTICALS's director compensation table. Totals are the company's own disclosed totals.
How this board is paid
Company policy: AGIOS PHARMACEUTICALS pays directors a $50,000 cash retainer and $400,000 in RSUs/Options. As stated in AGIOS PHARMACEUTICALS's FY2025 proxy.
Committees
Science and Technology
The full AGIOS PHARMACEUTICALS compensation record
free company briefThis page is one person within AGIOS PHARMACEUTICALS's record. The company brief lists every named executive, each linking to their own page.
Peer companies
named in the AGIOS PHARMACEUTICALS proxy · each links to its own free briefCompensation, the day it’s disclosed
The CompBrief Daily Digest lists the newest executive and director compensation disclosures as companies file them.
How this record is built
Every figure on this page is one figure from a public SEC filing, printed as the filing states it and cited to the document. Compensation totals are AGIOS PHARMACEUTICALS's own disclosed totals, not summed by Velarion. Insider transactions are read from Form 4 filings and cover every line filed since the most recent proxy. Nothing is estimated by Velarion; where the company does not disclose a value the cell reads "—", and a section appears only where the company discloses the data. Corrections: records@velarion.ai.